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S U M M A R Y
Objective: To determine the impact of missed visits on CD4 cell count with HIV disease in a Midwest
clinic.
Methods: This was a mixed method study consisting of a quantitative retrospective cohort study of
missed clinic visits among HIV-infected patients, and a qualitative study to collect information on factors
impacting appointment attendance. A drop in CD4 cell count greater than 50 cells/mm3 from baseline
was the primary outcome variable for the quantitative study. The exposure variable was missed visits.
Results: Of 77 patients, 16.4% experienced the outcome of interest. Lower visit proportions increased the
risk of a CD4 drop (hazard ratio 0.0188, 95% conﬁdence interval 0.001–0.292). For each 10% increase in
the missed visit proportion, the risk of a CD4 drop of >50 cells/mm3 from baseline increased by 33%.
Qualitative data suggested that stigma, external support, and physician–patient interactions impacted
engagement in care.
Conclusion: These results may help providers increase patient motivation and ability to attend clinic
appointments.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Advances in medical care have resulted in an increase in the
number of people living with HIV.1 In turn, medical care for HIV-
infected patients must evolve to focus on retaining patients in
long-term care. The negative impact of missed visits on subsequent
mortality among HIV-infected patients has been examined in
several recent studies.2,3 For example, it has been found that
individuals most at risk of appointment non-adherence come from
populations with the highest incidence of HIV — including African
American women and people with a low socioeconomic status.4–6
This may, in part, contribute to the observation from the Women’s
Interagency HIV Study of a disproportionate beneﬁt in HIV survival
over time following the widespread use of combination antiretro-
viral therapy, with women experiencing a smaller rate of decline in
death rate than men.7 In the USA, HIV-infected patients face
concurrent problems such as housing instability, lack of medical
insurance, and lack of access to medical facilities.8 These factors
complicate patient appointment adherence.* Corresponding author. Tel.: +1 402 559 8283; fax: +1 402 559 7259.
E-mail address: kmislam@unmc.edu (K.M. Islam).
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on clinical outcomes for HIV-infected patients. Missed visits
have been associated with a higher incidence of opportunistic
infections, AIDS-deﬁning illness, and death.2,3 However, few
studies have examined speciﬁc barriers to clinic visits that must
be identiﬁed before effective interventions can be put in place.
This study was developed to better understand the reasons for
missed visits, in order to develop optimal strategies to improve
clinical outcomes. Our goal was to develop opportunities to
improve engagement in clinic care from the development of a
‘no show’ proﬁle speciﬁc to the patient load of the University
of Nebraska Medical Center HIV Clinic and Nebraska AIDS
Project.
The objectives of this study were to determine the relation-
ship between missed outpatient visits and health outcomes
related to HIV infection and to identify barriers and facilitators
to retention in clinical care. The primary study outcome was a
drop in CD4 + T-lymphocyte count greater than 50 cells/mm3
from the baseline CD4 + T-lymphocyte measurement. This
objective was supplemented with information from the devel-
opment of a proﬁle of ‘no show’ patients in order to better
understand the factors affecting patients with high rates of
missed visits.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study design
Our study used a mixed methods approach with two parts. Part
I, the quantitative portion of the study, was a retrospective cohort
study aimed at determining the association between missed
outpatient visits and clinical outcomes related to HIV infection.
This portion of the study was also used to identify patient
characteristics associated with high rates of missed appointments.
Part II was a qualitative study aimed at collecting data on barriers
and facilitators to appointment attendance by patients at a
university medical center HIV clinic and the local AIDS service
organization.
For the quantitative portion of the study, all HIV-infected
patients presenting at the study clinic between January 1999 and
December 2000 were considered for inclusion, and data were
collected until December 2008, giving a follow-up period of 9
years. The primary exposure variable was missed visit status,
which was recorded as the proportion of visits attended over the
total number of visits scheduled during the period of interest.
Urgent care and subspecialty visits were excluded. Consistent with
other studies, only missed visits where a patient did not call the
clinic to cancel or reschedule were included in the missed visit
measure.9,10 A counting rule was established to identify missed
visits. For this study, visits were not included in the missed visit
proportion if the patient missed his/her appointment due to
hospitalization.
Landmark analysis was used to model the risk of non-
adherence. Patients were classiﬁed by the number of missed
appointments during the landmark period, and then patient
characteristics were examined to identify variables signiﬁcantly
related to a higher proportion of missed visits (Figure 1). A
stratiﬁed compliance method was used to account for the varying
levels of illness in patients to adjust for unequal likelihood of
missed visits. Sicker patients are more likely to have more
appointments and thus more opportunities to miss their
appointments. Therefore, the landmark period for patients
presenting with baseline CD4 + T-lymphocyte counts of 100
cells/mm3 was 1 year, as such patients are usually scheduled for
more frequent clinic visits. The landmark period for patients
presenting with baseline CD4 + T-lymphocyte counts >100 cells/
mm3 was 3 years. The proportion of missed appointments was
examined, rather than the total number of medical appointments,
to reduce potential confounding associated with individual
variations in the frequency of scheduled appointments. For the
purposes of the analysis, missed visit proﬁles were divided intoInitial visit 
(Jan 1999–
Dec 2000) 
End of compliance period: 
calculate missed visit 
proportion and collect 
baseline information
a
Landm
Figure 1. Landmark analysis design (aEnd of compliance period is 1 year after the ﬁrst v
years after the ﬁrst visit for patients with a CD4 count of >100 at their initial visit (laquartiles (i.e., patients with 0–25% visit attendance were assigned
to the ﬁrst quartile, 26–50% visit attendance to the second
quartile, etc.).
Patients were followed until December 2008. The outcome of
interest was a drop in the CD4 + T-lymphocyte count of at least 50
cells/mm3 from the baseline measurement, as this is generally
recognized as a clinically signiﬁcant decrement and more than the
biological variation in the assay. Also a fall in CD4 count is an
indication of possible treatment failure.11 For HIV-infected
patients receiving antiretroviral therapy, routine laboratory
monitoring is associated with improved health and survival
compared to clinical monitoring alone.12,13 Monitoring patients
with CD4 cell counts has been shown to be cost-effective.14
We invited patients accessing services at a community-based
organization (the Nebraska AIDS Project or NAP) and/or the
University of Nebraska Medical Center (UNMC) HIV Clinic to take
part in the qualitative portion of the study. Potential participants
were recruited from those who attended free daily lunches at NAP
or those who were regular patients at the UNMC HIV Clinic.
Interviews were conducted on site at the clinic.
2.2. Study population and sample size
The initial population for this study consisted of all HIV-
infected patients presenting to the study HIV clinic between
January 1999 and December 2000.
A total of 215 patients were identiﬁed during the deﬁned
timeframe. From this sample we eliminated 138 patients due to
missing information on clinic visits, resulting in a sample of 77
patients. Many of those excluded were being seen by outside
providers but their records were being maintained at the study
clinic in order to qualify for federally-funded Ryan White CARE Act
services; the study site is the sole site that administers these
services for the region. Other patients were excluded due to loss to
follow-up, incarceration, or moving away from the area served by
the study clinic.
We included patients who had survived at least 6 months after
their initial clinic visit, patients over the age of 19 years, and
women who were not pregnant during the study period. Patients
who died within 6 months of clinic enrollment were excluded
because there was insufﬁcient information to calculate a missed
visit proportion to deﬁne compliance. Pregnant women were
excluded because adherence to antiretroviral therapy during
pregnancy is higher than for non-pregnant women.15 Patients
under the age of 19 years (the age of majority in Nebraska) were
excluded because the main interest of this study was the adult
population, and children are not in control of whether or not theyark period End of 
follow-up 
(Dec 2008) 
Build hazard 
model with all 
patients with drop 
in CD4 >50 from 
baseline 
isit for patients with a CD4 count of <100 at their initial visit (landmark group 1), 3
ndmark group 2)).
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follow-up during the landmark period were also excluded since
they did not have appointment attendance data for the entire
exposure period.
Inclusion criteria for the qualitative portion of the study
were: being a person living with HIV/AIDS, English-speaking, not
pregnant, and over the age of 19 years. Non-probability
convenience sampling was used to identify participants for
the interview portion of the study. The total number of
participants interviewed was determined by theoretical sam-
pling, i.e., conducting interviews until patterns emerged from
the data and a saturation of relevant information was reached.16
Fourteen participants between the ages of 24 and 53 years
completed the exploratory semi-structured interviews, includ-
ing eight women and six men. Eight participants from the AIDS
service organization and six participants from the clinic
participated.
2.3. Data collection methods and measures
Quantitative measures were collected from the clinic database
and patient charts and included: date of ﬁrst clinic visit, date of
death, insurance status, demographic information and patient
status (active/inactive), baseline CD4 + T-lymphocyte count, base-
line viral load, number of attended visits, number of failed visits,
total number of visits, date at which a drop in CD4 + T-lymphocyte
count occurred, CD4 + T-lymphocyte count at drop, and ﬁnal
CD4 + T-lymphocyte count.
Data were collected for the qualitative portion of the study by
interviewing participants. Each audio-recorded interview lasted
between 15 and 30 min and consisted of three main areas of
discussion: (1) a rapport-building conversation on the person’s
identity as a person living with HIV/AIDS, (2) aspects of
appointment adherence, including issues with accessing clinic
appointments, perceived beneﬁts of care, and difﬁculties they face
in keeping clinic appointments, and (3) social support related to
appointment adherence and managing their illness (Appendix 1).
All protocols were approved by the Institutional Review Board of
the University of Nebraska Medical Center.215 patients f
selection cr
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visit propo
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Figure 2. Distribution of2.4. Analytical methods
For the quantitative data, initial descriptive and bivariate
statistical analyses were completed to describe study population
characteristics and to identify possible relationships between the
variables. Next, the data of all patients with both an initial and ﬁnal
CD4 count and landmark visit proportion were ﬁt with a
proportional hazard regression model. An alpha level of 0.05
was used for all statistical tests. Data were analyzed using both
SPSS and SAS software.
Data were analyzed using a drop in CD4 + T-lymphocyte count
>50 cells/mm3 from the baseline CD4 + T-lymphocyte measure-
ment as the outcome (Figure 2).
For the qualitative portion of the study, participant interviews
were transcribed verbatim and assigned a pseudonym. A grounded
theory approach was used for data collection and analysis.16
Analysis began by coding words and passages and then collapsing
codes into conceptual categories. Coding schemes were developed
to identify the emerging theories in the data. A second person,
trained in qualitative analysis and not otherwise involved in the
project, independently analyzed the data to provide inter-coder
reliability and validate the emerging themes to ensure themes
were not the sole interpretation of the ﬁrst author. A process of
discussion validated the emerging themes followed, where 100%
agreement was reached on the salient themes found in the
transcripts.
3. Results
3.1. Quantitative results
There were nearly twice as many men as women in this study;
the median age of the subjects was 44.51 years. There were more
patients in landmark group 2 (baseline CD4 count >100 cells/mm3)
for both men and women. The population was predominantly
uninsured, low income, and dependent on federal funding for their
HIV care (Table 1).
The demographics available for the initial 215 patients
identiﬁed did not differ signiﬁcantly from the demographics ofulfilled 
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Table 1
Baseline characteristics of study participants (N = 85)a
Characteristics Female (n = 28) Male (n = 57)
Age (years)
Mean 43.43 45.58
Range 28–70 27–70
Race
White 11 (12.9%) 34 (40%)
Black 9 (10.6%) 12 (14.1%)
Other 8 (9.4%) 11 (12.9%)
ADAP
Yes 18 (21.2%) 35 (41.2%)
No 10 (11.8%) 22 (25.9%)
Baseline CD4 (cells/mm3)
Mean 290.89 461.39
Median 234.00 342.00
Range 4–881 16–1428
Landmark groupb
Landmark 1 (baseline CD4 <100) 3 (3.5%) 12 (14.1%)
Landmark 2 (baseline CD4 100) 25 (29.4%) 45 (52.9%)
Visit proportion (N = 77)a
0–0.25 0 0
0.26–0.50 3 (3.9%) 6 (7.8%)
0.51–0.75 5 (6.5%) 12 (15.6%)
0.76–1.0 19 (24.7%) 32 (41.6%)
ADAP, AIDS Drug Assistance Program.
a This table describes the cohort at baseline; eight participants were missing
information necessary to calculate the missed visit proportion and were not
included in the analysis.
b Statistically signiﬁcant, p < 0.05.
Table 3
Bivariate analysis of CD4 count at baseline
CD4 count at baseline
Race
White 313.0
Black 364.0
Other 198.0
Gendera
Female 234.0
Male 342.0
Insurance status
ADAP 310.0
Landmark groupa
Landmark 1 17.0
Landmark 2 340.0
ADAP, AIDS Drug Assistance Program.
a Statistically signiﬁcant, p < 0.05.
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analysis was modeled using data from 77 patients. The majority of
patients were in the fourth quartile, meaning they attended 76–
100% of their appointments. There were no patients in the ﬁrst
quartile of 0–25% appointment attendance. Analysis of variance
(ANOVA) was conducted with each of the covariates to examine
the differences between each of the quartiles of landmark visit
proportion in the sample. There were statistically signiﬁcant
differences between the quartiles of landmark visit proportion for
patients who were recipients of the AIDS Drug Assistance Program
(ADAP) (F = 6.328, p = 0.003). Patients who kept more clinic
appointments were more likely to be recipients of ADAP when
compared to those with insurance (Table 2).
Table 3 shows the median CD4 counts at baseline for each of the
covariates. To examine the differences between median baseline
CD4 counts for race, ANOVA was conducted. Mann–Whitney tests
for nonparametric statistics were conducted to examine the
differences between the other covariates and median baselineTable 2
Bivariate analysis of landmark visit proportion quartiles (N = 77)
Q1 Q2 Q3 Q4
(n = 0) (n = 9) (n = 17) (n = 51)
Percent total 0 11.7% 22.1% 66.2%
Age (years), median N/A 44.0 44.0 45.0
Race
White N/A 3 (3.9%) 10 (13.0%) 24 (31.2%)
Black N/A 5 (6.5%) 5 (6.5%) 11 (14.3%)
Other N/A 1 (1.3%) 2 (2.6%) 16 (20.8%)
Gender
Female N/A 3 (3.9%) 5 (6.5%) 19 (24.7%)
Male N/A 6 (7.8%) 12 (15.6%) 32 (41.6%)
Insurance statusa
ADAP N/A 6 (7.8%) 5 (6.5%) 38 (49.4%)
Baseline CD4, median N/A 373.00 249.00 308.00
Landmark group
Landmark 1 N/A 0 4 (5.2%) 9 (11.7%)
Landmark 2 N/A 9 (11.7%) 13 (16.9%) 42 (54.5%)
N/A, not applicable; ADAP, AIDS Drug Assistance Program.
a Statistically signiﬁcant, p < 0.05.CD4 counts. The effect of gender was signiﬁcant; CD4 count at
baseline was lower for females than males (t = 2.683, p = 0.004).
By nature of the study design, the effect of landmark group was
also signiﬁcant; landmark group 2 had a signiﬁcantly higher
baseline CD4 count than landmark group 1 (F = 35.822, p < 0.001).
A visual representation of the primary outcome of a drop in
CD4 + T-lymphocyte count of >50 cells/mm3 from baseline is
provided in Figure 3. Ten patients had the event before the
landmark period, so under landmark guidelines they were
excluded. This left a total of 67 patients with 11 events.
Final hazard modeling was developed using data from 77
patients; 11 of these patients experienced the event of interest of a
drop in CD4 + T-lymphocyte count >50 cells/mm3 from the baseline
CD4 + T-lymphocyte measurement. Proportional hazard models
were used to estimate the effect of missed visits on the outcome of a
drop in CD4 + T-lymphocyte count of >50 cells/mm3 from the
baseline. Of the 77 patients used for modeling, 16.4% experienced
the outcome of a drop in CD4 count >50 cells/mm3 from baseline.
The landmark visit proportion was found to be signiﬁcantly related
to a drop in CD4 count >50 cells/mm3 from baseline (p = 0.0045).
Lower visit proportions increased the risk of a CD4 drop (hazard ratio
0.0188, 95% conﬁdence interval 0.001–0.292). The calculated hazard
ratio of 0.0188 corresponds to a per unit increase in the missed visit
proportion. This number can be used to estimate the percent change
in risk of the outcome based on a patient’s missed visit proportion:
for each 10% increase in the missed visit proportion (i.e., the more
appointments a patient misses), the risk of CD4 drop of >50 cells/
mm3 from baseline increases by 33%. Proportional hazard models
were also used to estimate the effect of gender on the outcome of
interest; this was not statistically signiﬁcant (p = 0.2457).
3.2. Qualitative results
Interviews with HIV-positive individuals currently receiving
medical care illustrated three themes related to appointment
adherence. They included the structure of medical care, value of
compliance, and motivation.
3.2.1. Structure of medical care
The narratives of this project’s participants reﬂect the impor-
tance of continuity of care and satisfaction with their health care
providers. Steven, a 53-year-old man recently engaged in care after
many years living with HIV, commented on his relationship with
the providers:
. . . when I was in Texas the little bit that I did go [to
appointments] you were more like a name and a number there.
Here, there’s. . .a personal relationship. They make you feel
comfortable.
Figure 3. Event date (CD4 drop >50) in relation to landmark visit proportions. Patients who experienced the outcome before the end of the landmark period are represented
by a dot only on the timeline. Patients who experienced the outcome after the landmark period have a dashed line from the end of the landmark period to the end of the study.
Patients with a CD4 drop greater than 50 from baseline whose event data extend later than the landmark period have a solid line with a dot on the event date.
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providers felt more respected and valued as a participant in their
own medical care.
Participants who trusted their physician’s ability to treat their
illness were more likely to describe themselves as fully in care.
This, along with physician–patient communication, was men-
tioned as an important structure of medical care. Don, a 46-year-
old participant engaged in care for over 10 years, gave this account
of his initial experiences with staff at the clinic:
When I ﬁrst came in [to the clinic] I was very skeptical. But the
staff, particularly [name deleted], she assured me. She helped
me realize. . .that if I did the right things I could still live a long
life. When I ﬁrst came here I. . . I looked like walking death. I
didn’t think I was going to, you know, every day I woke up was a
blessing but I didn’t think I would make it too long. And, she told
me I would get better and sure enough I did.
In contrast, participants who described negative experiences
with their health care providers were less likely to seek medical
care. Joe, a 42-year-old participant who struggled with medical
issues related to treatment at a facility in California, described his
challenges:
The doctors told me what I needed to do [for treatment]. When I
started the treatment it scared me because my T-cell count was
400 something and it dropped. And it scared me, but they said
‘‘Oh, you’ll be ﬁne.’’ It’s like playing poker. Luckily now I feel
ﬁne.
Joe continued on to express feeling a lack of control over his
health care decisions and the subsequent interruption in care he
experienced. Overall, participants characterized by positive
provider–patient relationships and a degree of control over their
health care were more likely to identify themselves as fully
engaged in care.3.2.2. Value of compliance
Across the narratives, participants who perceived adherence to
appointments as a valuable way to remain healthy while living
with HIV were more likely to report not missing scheduled
appointments. Many participants feared an interference with their
social roles if they were to get sick and identiﬁed this as an
important reason to remain adherent to all appointments. Natosha,
a 41-year-old mother of one, cited her daughter as an important
reason to be engaged in care:
. . .I have to take care of myself. I don’t want anything to happen
to me. I have a daughter to take care of so I want to live long as
much as I can, so I have to follow instructions so I can be able to
live long as much as I can and I don’t want to have any issues’
cause of not coming to my appointments.
Taking care of oneself in order to provide support for one’s
family was a key theme in the narratives.
In contrast, participants who did not perceive themselves as
vulnerable tended to ﬁnd continued appointment adherence less
important. Sarah, a 34-year-old recovering alcoholic/addict, did
not identify HIV as a signiﬁcant threat to her health:
I don’t know what being HIV-positive means to me. Just that I
have this, I guess, quote unquote disease that I just can’t get rid
of. I haven’t really made any changes due to being HIV-positive.
I’ve done all my lifestyle changes because of being a recovering
addict/alcoholic and that’s what’s more important to me
because it doesn’t matter whether I’m sick or not the drugs
and alcohol are going to take my life away if I don’t stop and it’d
be a lot sooner than the HIV.
The degree of illness participants experienced emerged as a
component of compliance value. Participants who became ill as a
result of their lack of appointment attendance often reported
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discussed his experience with dropping out of care:
When I was diagnosed my T-cell count was up real high and
they told me they didn’t recommend giving me any medica-
tions. . .and then I just kind of took off. ‘Pry sounds crazy but I
just went away and just quit seeing the doctor. I am now, I got
back into treatment after getting Hep C and losing a bunch of
weight. . .I can just tell my body doesn’t feel the same way. . .
Those participants who categorically expressed other priorities
or a belief that they were ‘too healthy’ were more likely to report
repeatedly missing clinic visits.
3.2.3. Motivations
Participant narratives identiﬁed both positive and negative
external inﬂuences in their HIV care. Stable, in-care participants
acknowledged the importance of support from family, friends,
partners, and other people living with HIV. Spirituality was also
singled out as a means of support for staying in care. In contrast,
narratives among participants who reported missing clinic
appointments reﬂected negative inﬂuences from stigma, loneli-
ness, and unsupportive family environments. Sarah discussed the
problems she had with her family:
It’s funny, my friend had it [HIV] and none of my friends or
family had issues with it, they were like ‘‘Oh, ok’’ but then when
they heard that I was sick, and not one of them have asked me
directly, and they’re just like ‘‘Ugh’’ and if they’re drinking water
or whatever, they’ll make comments and snide remarks about
being HIV-positive.
Fear of disclosure was reported across the narratives. The
degree to which a participant feared others ﬁnding out about his/
her HIV status was often indicative of that person’s engagement in
care. Dan, a 24-year-old patient who was diagnosed with HIV 3
years ago, declared that he worried ‘‘all day every day’’ about
people ﬁnding out. This apprehension affected Dan’s physical
health as well as his ability to seek out support and other services.
He explained:
It’s like once I leave this clinic everything I just talked about
stays in and I hate to take it outside of the clinic with me. . .I’ve
actually looked very closely at [local ASO] into what it’s about,
about joining. BUT there’s a lot of people that hangs around
[local ASO] that I may know. . .That’s probably the biggest thing
keeping me away is just knowing you know, is there people
there. I swear, you don’t even know, before I even walk into this
clinic I peek in the door, I won’t come in if there’s someone
I know. . .my blood pressure tends to rise on the day of my
appointments, kinda being horriﬁed that I’ll walk into the lobby
area or the waiting room into a room full of people that I may
know.
The narratives indicated that positive external support provid-
ed ongoing motivation to take care of one’s health, while
disincentives like stigma and fear of disclosure inhibited appoint-
ment adherence.
Self-reliance was categorically identiﬁed by nine participants as
a motivation for staying healthy and remaining in care. In contrast,
participants who seemed apathetic about their HIV diagnosis often
reported missing visits because they were busy, ‘just lazy’, or they
forgot about the appointment. Antonio, 41 years old, reported
being ‘‘very depressed’’ in the 2 weeks after his diagnosis, but
quickly turned things around; he stated:
After those two weeks I take control of everything. Just by
myself. I just start to think about what I was gonna do. I got outof that depression, I started to get a little bit more concerned
about my health in general, not just about HIV. And actually. . .I
don’t regret, and I think I am having better lifestyle because I
focus more on taking care. It is even better.
Participants whose narratives identiﬁed their HIV diagnosis as a
turning point for positive life changes were more likely to report
being adherent with scheduled clinic visits. Charles, a man in his
mid-ﬁfties who reportedly ‘‘never misses an appointment’’, talked
about the changes his HIV diagnosis made in his life:
I think that I have learned a lot of positive things from it [the HIV
diagnosis]. I’ve learned how to be patient. I’ve learned how to be
tolerant. You learn, kinda see how some people perceive you
and stuff like that, and being tolerant you know what you’re
going through so you know what other people are probably
going through too, so you’re more tolerant to what your
surroundings are, people around you.
Maintaining positive relationships with friends, family, and
partners and continuing to be optimistic about life serves as
motivation for patients to make their clinic appointments and be
proactive in their medical care. In contrast, participants who did
not mention any external support in their HIV experience or who
identiﬁed negative inﬂuences like stigma or fear of disclosure were
less likely to report always adhering to clinic appointments.
4. Discussion
While the majority of patients included in the study attended
between 76% and 100% of their scheduled appointments, we
observed skewed appointment adherence. Missed visits are not
likely to be causally responsible for the higher risk of a CD4 drop
from baseline, but are likely to be a risk factor for negative outcome
for patients living with HIV. Our study data suggest that for a 10%
increase in the missed visit proportion (i.e., the more appointments
a patient misses), the risk of a CD4 drop of >50 cells/mm3 from
baseline increases by 33%. These ﬁndings conﬁrm those of other
studies.10
CD4 cell counts can be an early predictor of treatment failure
during antiretroviral therapy, manifested either by a sustained
decrease or failure to increase over time on treatment.17 Reasons
for missed visits are complex.18 The qualitative interview with
the patients highlighted a few factors that can reduce the missed
visit proportion for long-term care of patients living with HIV. It
is important to establish a positive physician–patient relation-
ship and to understand patient’s pressing issues such as stigma
and the need for external support; this could improve adherence
to scheduled visits for long-term care. Factors established from
the qualitative portion of the study can be considered as a ‘no
show proﬁle’ for missed visits, as the qualitative sample was a
subset of the study population. These factors are negative
relationships with health care providers, less control over care,
perceived ‘too healthy’, lack of external support, and experiences
of negative inﬂuences, such as stigma and fear of disclosure of
HIV status.
Limitations to this study include the small sample size and
retrospective nature of the quantitative analysis. However, the
retrospective nature also provided strengths by allowing for
inspection of data over an 8-year period. Unknown confounders
and missing data may distort associations and complicate
interpretations. Possible confounders in this study include
undocumented substance abuse and mental illness.
The qualitative portion of the study provides fundamental,
theoretically grounded attitudes and perceptions related to
outpatient appointment adherence for people living with HIV.
A. Walburn et al. / International Journal of Infectious Diseases 16 (2012) e779–e785 e785A small, diverse group of people living with HIV recounted
stories about their identities as HIV-infected individuals, their
perceived barriers and facilitators to appointment adherence,
and their experiences with the health care system. These
narratives highlight the important roles that stigma, external
support, and physician–patient interactions play in understand-
ing long-term engagement in care.
A web of determinants impact a patient’s ability and motivation
to attend scheduled appointments. The practice of clinical
medicine at an individual level is critical to ensure that patients
remain healthy while living with HIV. In addition to this, however,
providers must bridge the gap between knowledge of a patient’s
physical condition and the outside factors that affect his/her
disease. The themes identiﬁed through interview analysis may be
useful for health care providers in shaping an ecological method of
HIV care. Patient interviews identiﬁed several aspects of the care
they receive at the UNMC clinic as beneﬁcial. The friendly
atmosphere at the clinic coupled with the encouragement of
clinic staff were mentioned numerous times and should be
considered crucial to engaging patients in care. Spending time
with patients to identify pressing needs may help ameliorate the
disproportionate impact that socioeconomic factors have on HIV
patients. By helping people living with HIV identify solid support
systems and needs outside of HIV-related care, providers at the
UNMC clinic may increase their patients’ motivation and ability to
attend clinic appointments.
In conclusion, many studies of HIV patient care have dealt
primarily with superﬁcial demographic and background vari-
ables. This study went beyond the one-dimensional, clinical
view of HIV to identify factors that inhibit engagement in HIV
care. Results from this study reﬂect the need to take an
ecological approach to HIV care. By working with patients to
treat not only their clinical symptoms, but also to address
outside issues like stigma, social support, and other pressing
needs, providers may be able to improve both individual health
and population outcomes.
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2012.06.004.References
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